Apoquel Side Effects for Dogs

Apoquel (oclacitinib maleate), manufactured by Zoetis, is one of the most widely prescribed allergy medications in veterinary medicine. FDA-approved in 2013 for dogs 12 months or older, it works by selectively inhibiting Janus Kinase 1 (JAK1) — an enzyme that drives the itch and inflammation signals in dogs with allergic dermatitis and atopic dermatitis. Apoquel has been used in millions of dogs since its launch and has an extensive safety record in both investigational studies and post-market surveillance. But that record includes genuine concerns that every dog owner deserves to understand fully: immune suppression, increased infection risk, the documented cancer warning on the FDA label, and what those post-approval adverse event reports actually show. BestiePaws.com™ presents the complete picture — directly from FDA, DailyMed/NIH, and 2025 peer-reviewed literature.

• 1
  What are the bad side effects of Apoquel in dogs? From the FDA-approved label (DailyMed/NIH): the most common adverse reactions in the clinical trial were diarrhea (4.6%), vomiting (3.9%), anorexia (2.6%), new skin lumps (2.6%), and lethargy (2.0%) — most resolved spontaneously. Lab changes: decreased white blood cells (neutrophils, eosinophils, monocytes), decreased globulins, increased cholesterol, and increased lipase. Post-approval reports (decreasing frequency): vomiting, lethargy, anorexia, diarrhea, elevated liver enzymes, skin infections (crusts, pyoderma, pododermatitis), seizures, increased water intake, demodicosis, tumors/neoplasms, lymphoma, and death.

  The DailyMed/NIH prescribing information (Zoetis 2020 post-approval update) lists adverse events from post-approval voluntary reporting in decreasing order of frequency: vomiting, lethargy, anorexia, diarrhea, elevated liver enzymes, dermatitis (crusts, pododermatitis, pyoderma), seizures, polydipsia, and demodicosis. The PMC peer-reviewed safety review (Nederveld et al., received June 2024, published May 2025, JVPT) confirms: “In the oclacitinib postapproval PV surveillance, the types and rank order of frequency of reported adverse events were similar to the premarketing field studies, with diarrhea, anorexia, and lethargy being the most frequently reported adverse events.” PetDermatologyClinic.com (board-certified veterinary dermatologist DACVD) notes the product insert side effects as: vomiting, diarrhea, lethargy, anorexia, SQ or dermal masses, decreased leukocytes, decreased globulins, increased cholesterol, and increased lipase — consistent with the JAK inhibitor class used in humans for rheumatoid arthritis and psoriasis.
• 2
  Does Apoquel cause cancer in dogs? The FDA-approved label contains an explicit warning: “APOQUEL may increase susceptibility to infection, including demodicosis, and exacerbation of neoplastic conditions.” This means the label warns that existing tumors may worsen, and that cancer-surveillance mechanisms may be impaired. The label does NOT say Apoquel causes new cancers in otherwise healthy dogs — but cancers, lymphoma, and tumors ARE listed in post-approval adverse event reporting. No controlled study has established direct causation. Dogs with existing cancer should NOT receive Apoquel.

  BestiePaws.com™ (January 2026): “Apoquel’s FDA-approved label contains explicit warnings that the medication ‘may increase susceptibility to infection and exacerbation of neoplastic conditions’ — medical jargon for ‘could worsen existing tumors or allow new cancers to develop.’ These warnings weren’t added casually; they reflect observations from safety studies and post-market surveillance reports documenting tumor development in treated dogs.” The Zoetis 180-day extension safety study (179 dogs) found 11 abnormal health events post-study, including 6 dogs euthanized for suspected malignant neoplasms, 2 dogs with Grade II mast cell tumors, 1 dog with B-cell lymphoma, 2 dogs with apocrine gland adenocarcinoma, and 1 dog with an oral spindle cell sarcoma. However, association does not equal causation — atopic dermatitis itself causes chronic inflammation that predisposes dogs to certain tumors. Dr. Nancy Reese (DogCancer.com): “Having an association of being on Apoquel versus something else causing it is really hard to prove.” The risk-benefit decision should always be made with your vet based on your individual dog’s health history.
• 3
  What are Apoquel’s long-term side effects in dogs? Long-term Apoquel use carries sustained immune suppression due to ongoing JAK1 inhibition. Known documented long-term concerns from FDA label and post-approval surveillance: increased susceptibility to bacterial infections (pneumonia, deep skin infections), disseminated fungal infections, demodicosis (mite overgrowth), worsening of pre-existing tumors, development of neoplastic conditions, and persistent lab changes (decreased leukocytes, increased cholesterol). Regular veterinary monitoring — including periodic blood panels — is recommended for dogs on long-term Apoquel.

  BestiePaws.com™ (November 2025) notes the FDA expanded its safety communication since 2015 to include: “Serious infections: cases of bacterial pneumonia, deep skin infections, and disseminated fungal diseases in Apoquel-treated dogs.” The mechanism is pharmacological: Apoquel blocks JAK1 enzymes that are not only involved in itch but in immune surveillance — specifically the monitoring system that detects and destroys abnormal cells, invading pathogens, fungi, and bacteria. BestiePaws.com™ (January 2026) describes this as: “Think of Apoquel as throwing a blanket over multiple fire alarms simultaneously. It’s effective at silencing the noise (itching), but you’re also muting alarms that signal legitimate threats like infections or abnormal cell growth.” A board-certified veterinary dermatologist (PetDermatologyClinic.com) confirms: secondary infections prevent drug efficacy and must be treated concurrently. The PMC 2025 safety review (JVPT) found the safety profile to be extensively evaluated with diarrhea, anorexia, and lethargy as the most common long-term reported events — broadly consistent with the pre-approval profile, suggesting the drug is not significantly more dangerous with time in most dogs. Annual bloodwork and periodic dermatologist assessment are the standard of care for long-term Apoquel patients.
• 4
  What happens if you stop Apoquel suddenly? Apoquel clears the dog’s system rapidly — within approximately 24 hours. Stopping suddenly will not cause a withdrawal syndrome in the pharmacological sense, but rebound itching is well-documented: the allergy symptoms that Apoquel was suppressing return, often intensely. Some dogs experience a rebound flare more severe than their pre-treatment baseline. A veterinary dermatologist may bridge the gap with a short course of steroids when transitioning off Apoquel. Never stop abruptly without consulting your vet if switching to a new medication.

  PetDermatologyClinic.com (board-certified DACVD): “Rebound itch [is] reported on stopping. Steroids can be used as a bridge when stopping.” Unlike some medications that require a taper, Apoquel does not require dose reduction before stopping — but the clinical consequence of stopping is the return of the underlying condition. BestiePaws.com™ (January 2026): “Apoquel clears the system in 24 hours” — meaning its anti-itch effect has a very short duration, which is both an advantage (rapid assessment of efficacy; quick discontinuation if side effects occur) and a disadvantage (daily dosing required; no protective window after missed doses). The rapid clearance is why some dermatologists recommend starting with Apoquel rather than Cytopoint for new patients — if a dog reacts poorly, the drug is out of the system within a day, whereas Cytopoint’s effects last 4–8 weeks. If you plan to switch your dog from Apoquel to Cytopoint or another medication, discuss the transition timeline with your vet — in some cases, an overlap period or steroid bridge is recommended.
• 5
  Is there an Apoquel FDA warning I should know about? Yes — two key warnings on the FDA-approved label: (1) “APOQUEL may increase susceptibility to infection, including demodicosis, and exacerbation of neoplastic conditions” — this means existing cancers may worsen and immune defenses are reduced; (2) Since 2015, the FDA expanded safety communication to specifically include serious infections: bacterial pneumonia, deep skin infections, and disseminated fungal diseases in Apoquel-treated dogs. These are not rare theoretical risks — they are documented in post-market surveillance.

  BestiePaws.com™ (November 2025): “While warnings regarding potential side effects were included from the outset, heightened scrutiny has been applied since 2015, when reports of severe adverse reactions were increasingly documented. These warnings emphasize that Apoquel suppresses the immune system, which can increase susceptibility to infections, exacerbate pre-existing conditions, and, in rare cases, contribute to the development of cancers.” The label also specifies: “APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches.” Additionally, Apoquel is not FDA-approved for dogs under 12 months of age — in pre-approval studies at 3× and 5× the therapeutic dose, puppies under 12 months developed demodicosis and pneumonia at unacceptable rates (PetDermatologyClinic.com DACVD). The complete prescribing information and current label are available at DailyMed (dailymed.nlm.nih.gov) — search “oclacitinib.”
• 6
  How long can a dog stay on Apoquel for itching? The approved protocol: twice daily for up to 14 days (induction phase), then once daily for maintenance — with no specified maximum duration. The FDA label does not cap long-term use. Apoquel has been used in many dogs for several years continuously. However, regular veterinary monitoring (periodic blood panels, physical exams) is the standard of care for long-term use. Dogs with seasonal allergies may benefit from cyclic use (2–4 months/season) rather than year-round dosing to minimize cumulative immune suppression.

  DailyMed/NIH prescribing information: “0.18 to 0.27 mg oclacitinib/lb body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy.” No stated maximum duration in the label. The PMC 2025 safety review (JVPT, Nederveld et al.) confirmed that the Kynetec PetTrak dataset showed continuous use in millions of dogs from January 2014 through February 2024 — a 10-year safety record in real-world practice. Dr. Nancy Reese (DogCancer.com): “If an animal doesn’t need it, I wouldn’t give it. Or they may not need to be on it year-round. Or they might just have a seasonal allergy where you could give it for two months and then keep them off the rest of the year.” BestiePaws.com™ recommends: for dogs on Apoquel longer than 3–6 months, discuss with your vet whether periodic blood panels (CBC with differential, chemistry panel) are warranted to monitor for white blood cell changes, liver enzymes, cholesterol, and lipase — particularly in senior dogs or dogs with any prior history of infection or tumor.
• 7
  How does Apoquel make a dog feel? Most dogs on Apoquel experience significant, rapid relief from itching — typically within 4–24 hours of the first dose. Owners commonly report their dog sleeping better, resuming normal play, and stopping self-destructive scratching and biting. Some dogs experience mild initial GI effects (loose stool, decreased appetite) that typically resolve within the first week. A small percentage of dogs experience lethargy at the start of treatment. Most dogs feel dramatically more comfortable and comfortable — but the underlying allergy is not cured.

  BestiePaws.com™ (January 2026): “Both [Apoquel and Cytopoint] reduce itching within 4–24 hours.” The DailyMed field study confirmed that in the majority of treated dogs, adverse effects like diarrhea, vomiting, anorexia, and lethargy “spontaneously resolved with continued dosing” — suggesting these are mild adjustment reactions, not persistent harm. In terms of behavioral and comfort improvement: Apoquel’s reputation among veterinary practitioners and dog owners is overwhelmingly positive for relieving the acute suffering of severe allergic itch — the scratching, skin damage, sleep disruption, and behavioral distress that untreated atopic dermatitis causes. The key message: Apoquel relieves symptoms — it does not treat the underlying cause. Dogs who stop Apoquel without addressing the root allergy (food allergy elimination diet, environmental allergen avoidance, allergen-specific immunotherapy) will return to the same level of discomfort. The goal of long-term management should be finding the lowest effective dose — or cyclic use — while pursuing allergen identification.
• 8
  Is Apoquel safe for humans — can people take it? No — Apoquel (oclacitinib) is a veterinary drug approved only for dogs in the United States. It is NOT approved for human use. The same class of drugs — JAK inhibitors — includes human medications such as tofacitinib (Xeljanz), upadacitinib (Rinvoq), and baricitinib (Olumiant), but these are different formulations with different safety profiles, doses, and regulatory approvals. Never use veterinary Apoquel on humans. If human accidental exposure occurs, call Poison Control at 1-800-222-1222.

  PetDermatologyClinic.com (board-certified DACVD) notes: “Other drugs in the same drug class as Apoquel include drugs for humans for rheumatoid arthritis, psoriasis, and cancer. In humans, the side effects of drugs in the JAK inhibitor class of drugs include: neutropenia, anemia, thrombocytopenia, increased liver values, increased cholesterol, UTI, weight gain, herpes zoster.” These human JAK inhibitors have FDA black box warnings for serious infections, malignancy, blood clots, and death in humans — information that underscores why JAK inhibitor class drugs require careful monitoring regardless of species. Apoquel’s veterinary formulation is dosed specifically for canine physiology and is not interchangeable with any human product. If your dog accidentally ingests an excessive amount of Apoquel (the chewable/flavored tablet formulation is particularly palatable), call ASPCA Animal Poison Control at (888) 426-4435 immediately.
• 9
  What is Apoquel 16 mg — who is it for? Apoquel 16 mg is the most commonly prescribed tablet size, appropriate for medium to larger dogs (approximately 30–130 lbs at maintenance dosing). Apoquel comes in three tablet sizes: 3.6 mg (small dogs, ~6–15 lbs), 5.4 mg (medium-small, ~15–30 lbs), and 16 mg (medium-large, ~30–130 lbs). The dose is weight-based: 0.18–0.27 mg/lb (0.4–0.6 mg/kg) per dose — your vet calculates the correct tablet size and dose for your individual dog.

  DailyMed/NIH: “The dose of APOQUEL (oclacitinib maleate) tablets is 0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy. APOQUEL may be administered with or without food.” The three available tablet sizes allow dosing flexibility across dog weights. Large dogs (over 130 lbs) may require one 16 mg + one smaller tablet to achieve therapeutic dosing — your vet will calculate this. There is currently no FDA-approved generic version of Apoquel in the United States. On September 19, 2024, the FDA approved Zenrelia (ilunocitinib) by Elanco — this is a different JAK inhibitor with the same indication, not a generic of Apoquel. Zenrelia is a non-selective JAK inhibitor (vs. Apoquel’s selective JAK1 inhibition), meaning it has a different safety profile that should be reviewed separately.
• 10
  What is a good alternative to Apoquel for dogs? The main FDA-approved alternatives: (1) Cytopoint (lokivetmab) — monoclonal antibody injection targeting IL-31 specifically; once every 4–8 weeks; minimal immune suppression; safer for dogs with cancer history or immune concerns; no age restriction; (2) Zenrelia (ilunocitinib) — new JAK inhibitor approved Sept 2024; same indication as Apoquel; different mechanism; (3) Cyclosporine (Atopica) — older immune modulator; effective but slower onset; (4) Allergen-specific immunotherapy (ASIT/allergy shots) — addresses root cause; (5) Steroids (short-term bridge); (6) Natural/multimodal approaches: omega-3 supplementation, medicated shampoos, allergen avoidance.

  BestiePaws.com™ (January 2026) provides the clearest Apoquel vs. Cytopoint comparison: “Apoquel is preferred for dogs needing immediate relief or daily management, while Cytopoint may be better for long-term use or for dogs sensitive to oral medications.” Cytopoint specifically targets only IL-31 (the primary itch-transmitting cytokine), leaving the rest of the immune system theoretically intact — making it the preferred choice for dogs with a cancer history, immunocompromised status, or ongoing serious infections. Dr. Nancy Reese (DogCancer.com): “There is a Cytopoint injection, which is a monoclonal antibody injection. It targets one very specific chemical that’s involved in itching, so for some animals that’s an alternative to Apoquel and maybe it’s a little less prone to affect the rest of the immune system.” For dogs where neither option is appropriate, a board-certified veterinary dermatologist (DACVD) referral is the recommended next step — they offer allergen testing, allergy immunotherapy, and the most current evidence-based options.

Sources: FDA DailyMed NIH dailymed.nlm.nih.gov (Apoquel oclacitinib maleate prescribing information; Zoetis 2020 post-approval update; FDA approved 2013 dogs ≥12 months; JAK1 selective inhibitor; dose 0.18–0.27 mg/lb BID ≤14 days then SID maintenance; field study 152 treated 147 placebo: diarrhea 4.6% vs 3.4%, vomiting 3.9% vs 4.1%, anorexia 2.6% vs 0%, lumps 2.6% vs 2.7%, lethargy 2.0% vs 1.4%; most spontaneously resolved; lab: decreased leukocytes/globulins; increased cholesterol/lipase; post-approval adverse events decreasing frequency: vomiting/lethargy/anorexia/diarrhea/elevated liver enzymes/dermatitis crusts pododermatitis pyoderma/seizures/polydipsia/demodicosis/benign+malignant+unclassified neoplasms/dermal masses papillomas histiocytomas/lymphoma/other cancers/death euthanasia; label warning: APOQUEL may increase susceptibility to infection + demodicosis + exacerbation of neoplastic conditions; NOT breeding/pregnant/lactating; 3 tablet sizes 3.6/5.4/16 mg); PMC pmc.ncbi.nlm.nih.gov/articles/PMC12066884 JVPT Nederveld et al. (received Jun 27 2024; revised Jan 16 2025; accepted Feb 6 2025; published May 2025; postapproval PV surveillance types+rank order similar premarketing; diarrhea/anorexia/lethargy most frequent; Zenrelia ilunocitinib FDA approved Sept 19 2024 same indication different drug; Kynetec PetTrak millions dogs Jan 2014–Feb 2024); BestiePaws.com™ Jan 9 2026 (Apoquel vs Cytopoint; JAK1+JAK3 blocked; IL-31 Cytopoint specific; 4–24 hrs onset both; Apoquel clears 24 hrs Cytopoint lasts 4–8 weeks; no age restriction Cytopoint; FDA label explicit warning neoplastic; tumor development safety studies post-market; “throwing blanket over fire alarms”); BestiePaws.com™ Nov 2025 FDA warnings (since 2015: bacterial pneumonia deep skin infections disseminated fungal; JAK1 tumor immune surveillance; tachyphylaxis cytokine adaptation; Zenrelia ilunocitinib Sept 2024); BestiePaws.com™ Mar 2025 long-term (Cytopoint minimal immune suppression; cancer history: Cytopoint preferred; JAK1 abnormal cell growth concern); petdermatologyclinic.com DACVD board-certified (≥12 months; demodicosis pneumonia at 3× 5× dose puppies; product insert: vomiting/diarrhea/lethargy/anorexia/SQ dermal masses/decreased leukocytes+globulins/cholesterol+lipase; JAK class human: neutropenia/anemia/thrombocytopenia/elevated liver/cholesterol/UTI/weight gain/herpes zoster; secondary infections prevent efficacy; rebound itch on stopping; steroids bridge; don’t stop abruptly without vet); dogcancer.com Dr. Nancy Reese (association vs causation hard to prove; seasonal use option; Cytopoint less immune system effect; weighing quality of life vs risks); ASPCA Poison Control (888) 426-4435 (accidental overdose)

Sources: DailyMed NIH (oclacitinib JAK1 selective inhibitor; FDA 2013; ≥12 months; 3.6/5.4/16 mg tablets; 0.18–0.27 mg/lb; BID ≤14 days then SID; label warning: susceptibility to infection + demodicosis + exacerbation neoplastic); BestiePaws.com™ Jan 2026 (4–24 hrs onset; Apoquel clears 24 hrs; Cytopoint 4–8 weeks); BestiePaws.com™ Nov 2025 (since 2015 bacterial pneumonia deep skin infections disseminated fungal); ASPCA (888-426-4435 24/7); Zoetis adverse events 1-888-963-8471; Lister Basile Wegenast JVECC April 2025 (overdose: immune suppression/GI/skin/lymph nodes)

Sources: DailyMed NIH (field study 152 treated vs 147 placebo; diarrhea 4.6%/3.4%; vomiting 3.9%/4.1%; anorexia 2.6%/0%; lumps 2.6%/2.7%; lethargy 2.0%/1.4%; most resolved spontaneously; ↓neutrophils/eosinophils/monocytes/globulin; ↑cholesterol/lipase; post-approval decreasing frequency: vomiting/lethargy/anorexia/diarrhea/elevated liver enzymes/dermatitis crusts pododermatitis pyoderma/seizures/polydipsia/demodicosis/neoplasms benign+malignant+unclassified/lymphoma/death; label: APOQUEL may increase susceptibility to infection + demodicosis + exacerbation neoplastic conditions; NOT breeding/pregnant/lactating; NOT <12 months); BestiePaws.com™ Nov 2025 (since 2015: bacterial pneumonia deep skin infections disseminated fungal; JAK1 tumor immune surveillance); BestiePaws.com™ Jan 2026 (Apoquel clears 24 hrs; Cytopoint IL-31 specific; Apoquel JAK1+JAK3 broad; FDA label explicit warning; tumor development safety studies post-market; cancer history Cytopoint preferred; Cytopoint no age restriction); petdermatologyclinic.com DACVD (secondary infections prevent efficacy; rebound itch; steroids bridge; do not stop abruptly); PMC 2025 JVPT Nederveld (postapproval PV consistent premarketing; diarrhea/anorexia/lethargy most frequent); Zoetis 180-day extension study (11/179 abnormal events; 6 euthanized malignant neoplasms; 2 mast cell Grade II; 1 B-cell lymphoma; 2 apocrine gland adenocarcinoma; 1 oral spindle cell sarcoma)

Sources: DailyMed NIH (complete adverse event profile; post-approval 2020 update; label warning; NOT: <12 months/breeding/pregnant/lactating; JAK1 selective inhibitor; BID ≤14 days then SID maintenance); BestiePaws.com™ Jan 2026 (Cytopoint IL-31 specific; no age restriction; preferred cancer history; Apoquel clears 24 hrs; FDA label explicit warning; 4–24 hrs onset); BestiePaws.com™ Nov 2025 (bacterial pneumonia deep skin disseminated fungal since 2015; JAK1 tumor surveillance); petdermatologyclinic.com DACVD (rebound itch; steroids bridge; secondary infections; ≥12 months only); PMC 2025 JVPT Nederveld (Kynetec PetTrak millions dogs 2014–2024; postapproval consistent premarketing; diarrhea/anorexia/lethargy; Zenrelia ilunocitinib FDA Sept 19 2024 different drug same indication non-selective JAK); dogcancer.com Dr. Nancy Reese (seasonal use option; Cytopoint monthly injection less immune system effect); ASPCA (888-426-4435)